Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Hidradenitis Suppurativa Companies

Hidradenitis Suppurativa (HS) is a chronic skin condition characterized by the formation of painful nodules, abscesses, and tunnels under the skin, typically in areas where skin rubs together. While there is no cure for HS, various pharmaceutical companies are actively involved in researching and developing treatments to manage symptoms and improve the quality of life for individuals with this condition.

Hidradenitis Suppurativa Key Companies

Latest Hidradenitis Suppurativa Companies Update

Positive Phase 3 results for bimekizumab (Sun Pharma): December 2023 saw promising news with BE HEARD I and II trials demonstrating significant improvements in pain and overall disease activity in HS patients treated with bimekizumab. This could lead to a new biologic option for moderate-to-severe HS.

Secukinumab (Novartis) emerges as a leading treatment: October 2023 research confirms Secukinumab's increasing adoption by dermatologists, solidifying its position as a key player in the HS treatment landscape.

AbbVie initiates Phase 2 trial for Upadacitinib: January 2024 news brings us another potential contender, with AbbVie investigating Upadacitinib, a JAK inhibitor, for HS treatment.

FDA approves intravenous Cosentyx (Novartis) for HS: June 2023 approval offers a new administration option for this biologic, potentially improving convenience for some patients.

List of Hidradenitis Suppurativa Key Companies in the Market

AstraZeneca (UK)

Pfizer Inc.(US)

GlaxoSmithKline plc. (UK)

Merck & Co., Inc. (US)

Johnson & Johnson Services Inc. (US)

Hidradenitis Suppurativa Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.